Literature DB >> 23857671

The CX3CL1/CX3CR1 reprograms glucose metabolism through HIF-1 pathway in pancreatic adenocarcinoma.

He Ren1, Tiansuo Zhao, Junwei Sun, Xiuchao Wang, Jingcheng Liu, Song Gao, Ming Yu, Jihui Hao.   

Abstract

One of the hallmarks of cancer is revised glucose metabolism that promotes cell survival and proliferation. In pancreatic cancer, the regulatory mechanism of glucose metabolism remains to be elucidated. In this study, we found that CX3CR1 is expressed in pancreatic cancer cells lines. Exogenous or transfected CX3CL1 increased glucose uptake and lactate secretion. CX3CL1 stimulated HIF-1 expression through PI3K/Akt and MAPK pathways. Furthermore, knockdown of HIF-1 blocked CX3CL1-modified glucose metabolism in pancreatic adenocarcinoma cells. In conclusion, the CX3CL1/CX3CR1 reprograms glucose metabolism through HIF-1 pathway in pancreatic cancer cells.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CX3CL1; GLUCOSE METABOLISM; HYPOXIA-INDUCIBLE FACTOR-1; PANCREATIC ADENOCARCINOMA

Mesh:

Substances:

Year:  2013        PMID: 23857671     DOI: 10.1002/jcb.24608

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  HIF-1 is a critical target of pancreatic cancer.

Authors:  Jihui Hao
Journal:  Oncoimmunology       Date:  2015-07-17       Impact factor: 8.110

2.  Diet-Induced Obesity Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma via CX3CL1/CX3CR1 Axis.

Authors:  Yue Sun; Xiao-Xin Zhang; Shan Huang; Hong Pan; Yan-Zhi Gai; Yao-Qi Zhou; Lei Zhu; Hui-Zhen Nie; Dong-Xue Li
Journal:  J Immunol Res       Date:  2022-04-18       Impact factor: 4.493

3.  Targeting the hypoxia pathway to treat pancreatic cancer.

Authors:  Lori A Erickson; W Edward Highsmith; Peiwen Fei; Jun Zhang
Journal:  Drug Des Devel Ther       Date:  2015-04-08       Impact factor: 4.162

4.  Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.

Authors:  Tiansuo Zhao; He Ren; Li Jia; Jing Chen; Wen Xin; Fan Yan; Jing Li; Xiuchao Wang; Song Gao; Dong Qian; Chongbiao Huang; Jihui Hao
Journal:  Oncotarget       Date:  2015-02-10

Review 5.  Research trends in pharmacological modulation of tumor-associated macrophages.

Authors:  Neng Wang; Shengqi Wang; Xuan Wang; Yifeng Zheng; Bowen Yang; Juping Zhang; Bo Pan; Jianli Gao; Zhiyu Wang
Journal:  Clin Transl Med       Date:  2021-01

Review 6.  Targeting hypoxic tumor microenvironment in pancreatic cancer.

Authors:  Jinxin Tao; Gang Yang; Wenchuan Zhou; Jiangdong Qiu; Guangyu Chen; Wenhao Luo; Fangyu Zhao; Lei You; Lianfang Zheng; Taiping Zhang; Yupei Zhao
Journal:  J Hematol Oncol       Date:  2021-01-13       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.